Microdosing, neuropsychedelia and psilocybin therapy are just a few of the topics that will be discussed at a free day-long seminar and webinar at UC Davis Health in Sacramento on March 23.
The Psychedelic Summit will bring together national experts to explore what the rapidly evolving field of psychedelics and neurotherapeutics may mean for neuropsychiatric and neurodegenerative diseases. These new treatment types may hold promise for anxiety, depression, substance use, obsessive-compulsive and post-traumatic stress disorders, among others.
David Lubarsky, vice chancellor of Human Health Sciences and CEO of UC Davis Health, will introduce the event. The Psychedelic Summit is hosted by the UC Davis Department for Psychiatry and Behavioral Sciences, the Institute for Psychedelics and Neurotherapeutics and the Behavioral Health Center of Excellence.
Speakers
David E. Olson, University of California, Davis
Psychedelics and Plasticity-Promoting Neurotherapeutics
Mark Geyer, University of California, San Diego
Neuropsychedelia: From Psychotomimetics to Psychotherapeutics
Joshua Wooley, University of California, San Francisco
Researching Psilocybin Therapy: Current Challenges and Future Prospects
Harriet De Wit, University of Chicago
Microdosing: Fact or Fiction?
Frederick Streeter Barrett, Johns Hopkins University
Neural and Psychological Mechanisms of Action of Classic Psychedelic Drugs
Dhakshin Ramanathan, University of California, San Diego
Beyond Psychedelics: Augmenting Mood Enhancing Effects with Personalized Plasticity-Based Interventions
Conor Liston, Weill Cornell Medicine
Probing and Rescuing Dysfunctional Brain Circuits in Depression
